Clinical trials: in Niger
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
This study aimed to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for…
- Trial name
- KALUMA (NCT05842954)
- Testing
- KLU156, Coartem
- Where
- 32 sites in Burkina Faso, Côte d’Ivoire and 10 more
- Volunteers
- 1,720 people
- Sponsor
- Novartis Pharmaceuticals
Mortality, Resistance Bacterial
Azithromycin for Child Survival in Niger: Mortality and Resistance Trial
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include…
- Conditions
- Mortality, Resistance Bacterial, Child, Only
- Trial name
- AVENIR (NCT04224987)
- Testing
- Azithromycin
- Where
- Niger
- Volunteers
- 864,493 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Trachoma
Azithromycin Reduction to Reach Elimination of Trachoma
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger.
- Trial name
- ARRET (NCT04185402)
- Testing
- Azithromycin
- Where
- Niger
- Volunteers
- 3,931 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pneumococcal Carriage
Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)
The aim of this study is to assess the impact of a mass campaign with a single, fractional dose of Pneumosil®, a PCV10, on VT carriage.
- Trial name
- fPCV (NCT05175014)
- Testing
- PCV10 full dose, PCV10 fractional dose
- Where
- Niger
- Volunteers
- 44,618 people, healthy volunteers welcome
- Sponsor
- Epicentre
Childhood Mortality
Mortality Reduction After Oral Azithromycin: Mortality Study
Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality.
- Trial name
- MORDORIMort (NCT02047981)
- Testing
- Azithromycin
- Where
- 6 sites in United States, Malawi and 3 more
- Volunteers
- 190,238 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Childhood Mortality
Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality.
- Trial name
- MORDORIIMortY5 (NCT03338244)
- Testing
- Azithromycin
- Where
- 2 sites in United States, Niger
- Volunteers
- 66,228 people
- Sponsor
- University of California, San Francisco
Trachoma, Chlamydia Trachomatis
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
Trachoma is a disease of poverty, which in the hyperendemic areas affects all individuals by the time they are two years old. Active disease is concentrated in children and occurs sporadically in adults.
- Trial name
- NCT00618449
- Testing
- Azithromcyin, Azithromycin
- Where
- 2 sites in United States, Niger
- Volunteers
- 1,139 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco